Monday, August 04, 2008


NanoViricides, Inc. Signs Rabies Agreement with CDC for Expanded Research

Study to Evaluate Usage Strategy for further Development towards Drug Approval

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB), (the “Company”) said that it has signed a Materials Cooperative Research and Development Agreement (MCRADA) with the United States Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia for rabies treatment study. The study, to be performed in collaboration with the CDC Rabies Program, is scheduled to begin soon.

“This study will expand on two successful animal studies of RabiCide™-I performed previously by the government of Vietnam,” said Eugene Seymour, MD, MPH, CEO of the Company, adding that “In those prior studies we achieved a 25% to 30% survival rate in animals that had already developed rabies. We believe this strong survival rate is a historical first achievement for any post-infection rabies treatment.”

“Collaborating with CDC in designing and conducting these studies is an important step forward,” said Anil R. Diwan, PhD, President of the Company, adding, “If the current studies are successful, we anticipate that this will be instrumental in helping our anti-rabies nanoviricide towards drug approval and widespread use across the world.”

The Company has previously reported that Yale Research Professor Thomas Lentz, a leading expert in antiviral therapeutics based on virus-cell binding, has joined the Scientific Advisory Board. Prof. Lentz studied the binding of rabies virus to various cell receptors and has performed pioneering research in this field. The Company believes that it has put together a strong team to tackle rabies.


Anonymous said...

a CURE for rabies, now being tested in a partnership with the CDC, a $300M annual market, and a company with a mkt cap of only $140M. what the HELL is wrong with this picture?

if ALL the company had was just this one drug and this one disease, wouldn't that value the company at five times the $300M annual drug mkt, or about ten times the current share price?

doesn't THIS ONE DRUG put share price of NNVC at $10?

the fact that NNVC is working on about half a dozen drugs, of which RabiCide is only one, and certainly not the most important or lucritive one.

Anonymous said...

NTRZ is making a move from down below .40 - I bought more at .41 -Cruiseguy..

Anonymous said...

Are you possibly rethinking DUG?

Anonymous said...

I bought more NNVC, today....I'd like to see one release that wasn't a paid for release by NNVC..


A said...

Dave, you asked:

Are you possibly rethinking DUG?

Yes, I'm thinking that not only should I be Long XLE with Calls, I should also be Short DUG with Puts.

Looking at all my energy charts, I can't help but anticipate one heck of a rally in Oil and even more so in Natural Gas. But, remember, I don't forecast, I trade the trends, looking for breakouts with stellar risk:reward parameters. So I will stand pat for now, ready to add to my energy longs should they reverse up, sooner rather then later I suspect.

Anonymous said...


very exciting pr's coming from NNVC.
I have been following you since '06, have you looked at PTSC again. It's showing a reversal

Anonymous said...

PTSC is interesting...

"I have to be VERY careful here as I am an advisor to Intellasys (the group associated with TPL that develops Chuck Moore’s Forth multiprocessor) and I am on the board of Patriot Scientific.TPL is a patent licensing company with a number of patent portfolios (microprocesors, flash memory, high-speed logic, etc.). It is the best I have seen at what it does. Unfortunately, there are two kinds of patent licensing companies. For diplomacy’s sake, I’ll call them forward-looking and backward-looking. ARM is a forward-looking licencing company and Acacia Research is a backward-looking licensing company. I’ll follow this post with another that explains the difference.

If you wish to invest in TPL’s Moore Microprocessor Portfolio (MMP), one way to do that is to buy stock in Patriot Scienific (PTSC). Patriot and TPL share MMP revenues. Patriot benefits from the MMP revenues without the overhead of TPL’s huge engineering and legal overhead.

The merits of Intellasys’s Moore multiprocessor (Seaforth) are a different discussion from whether to invest in the Moore Microprocessor Portfolio. The future for multiprocessors would be an interesting discussion, but Intellasys is a small part of TPL that is not a part of its association with Patriot (so there’s no avenue for investment)."


Anonymous said...

I'm in on NNVC with over half of my (tiny) investing fund. However, my personality is that of a skeptic and constant inquiry and examination.

I was reading an article in the Indian times recently where a doctor stated: "According to Dr Kochar, there are approximately 30 AIDS vaccine candidates in the clinical pipeline in various stages of testing today."

I know NNVC has products that target viruses other than AIDS. I wonder though, just playing a numbers game, if we can make the likely incorrect assumption that there are 30 competent competing products in the pipeline for each of NNVCs products, then the only way NNVC would succeed was if it really did make a breakthrough in the treatment of viruses.

Now lets just say NNVC has made a breakthrough. Surely some people must be privy to that knowledge? Some people would be loading up like crazy on the stock? There would be more industry buzz? Well, I've seen revolutionary innovations be marginalized before, but in the pharma industry?

Anyway... I just don't know :)

A said...

Half your portfolio invested and you, "...don't know?"